Scintigraphic assessment of gastrointestinal motility: a brief review of techniques and data interpretation

Madsen, J.

doi:10.1111/cpf.12089

Cited by 12 publications

(24 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several approaches based on a duplex technique with serial determinations of cross-sectional areas or 3-dimensional ultrasonography with volume algorithms have been introduced to assess gastric emptying [14,15]. Furthermore, transabdominal ultrasonography can be used to measure transpyloric flow [14,16].…”

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

“…Furthermore, transabdominal ultrasonography can be used to measure transpyloric flow [14,16]. Ultrasonography is easily accessible, noninvasive and does not expose the subject to radiation.…”

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

“…Ultrasonography is easily accessible, noninvasive and does not expose the subject to radiation. The method is operator-dependent, reliable only for liquid meals and difficult to use in obese subjects [14]. …”

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

“…99 Tc sulphur colloid radiolabelled scrambled egg is often used as a digestible solid component and indium-111 diethylenetriaminepentaacetic acid in water is used as a liquid marker. The scintigraphy approach also allows for the evaluation of small-intestinal and colonic motility [14]. …”

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

“…Fatty acids labelled with the nonradioactive isotope 13 C-octanoic acid can be used to measure gastric emptying as 13 C is absorbed in the intestine and excreted by breath [14]. The method has the advantage that it is easy to perform and inexpensive.…”

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

See 4 more Smart Citations

Motility Alterations in Celiac Disease and Non-Celiac Gluten Sensitivity

Sánchez

Berčík²,

Verdú³

2015

Dig Dis

View full text Add to dashboard Cite

Regulation of gut motility is complex and involves neuromuscular, immune and environmental mechanisms. It is well established that patients with celiac disease (CD) often display gut dysmotility. Studies have shown the presence of disturbed esophageal motility, altered gastric emptying, and dysmotility of the small intestine, gallbladder and colon in untreated CD. Most of these motor abnormalities resolve after a strict gluten-free diet, suggesting that mechanisms related to the inflammatory condition and disease process are responsible for the motor dysfunction. Motility abnormalities are also a hallmark of functional bowel disorders such as irritable bowel syndrome (IBS), where it has been proposed as underlying mechanism for symptom generation (diarrhea, constipation, bloating). Non-celiac gluten sensitivity (NCGS) is a poorly defined entity, mostly self-diagnosed, that presents clinically with IBS symptoms in the absence of specific celiac markers. Patients with NCGS are believed to react symptomatically to wheat components, and some studies have proposed the presence of low-grade inflammation in these patients. There is little information regarding the functional characterization of these patients before and after a gluten-free diet. A study suggested the presence of altered gastrointestinal transit in NCGS patients who also have a high prevalence of nonspecific anti-gliadin antibodies. Results of an ongoing clinical study in NCGS patients with positive anti-gliadin antibodies before and after a gluten-free diet will be discussed. Elucidating the mechanisms for symptom generation in NCGS patients is important to find new therapeutic alternatives to the burden of imposing a strict gluten-free diet in patients who do not have CD.

show abstract

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

Section: Brief Overview Of Methods To Assess Gut Motilitymentioning

confidence: 99%

See 3 more Smart Citations

Motility Alterations in Celiac Disease and Non-Celiac Gluten Sensitivity

Sánchez

Berčík²,

Verdú³

2015

Dig Dis

View full text Add to dashboard Cite

show abstract

Colonic transit in patients after anterior resection: prospective, comparative study using single-photon emission CT/CT scintigraphy

Russo

Gladman

2020

British Journal of Surgery

View full text Add to dashboard Cite

Background Bowel dysfunction after anterior resection is well documented, but its pathophysiology remains poorly understood. No study has assessed whether postoperative variation in colonic transit contributes to symptoms. This study measured colonic transit using planar scintigraphy and single‐photon emission CT (SPECT)/CT in patients after anterior resection, stratified according to postoperative bowel function. Methods Symptoms were assessed using the low anterior resection syndrome (LARS) score. Following gallium‐67 ingestion, scintigraphy was performed at predefined time points. Nine regions of interest were defined, and geometric centre (GC), percentage isotope retained, GC velocity index and colonic half‐clearance time (T½) determined. Transit parameters were compared between subgroups based on LARS score using receiver operating characteristic (ROC) curve analyses. Results Fifty patients (37 men; median age 72·6 (range 44·4–87·7) years) underwent planar and SPECT scintigraphy. Overall, 17 patients had major and nine had minor LARS; 24 did not have LARS. There were significant differences in transit profiles between patients with major LARs and those without LARS: GCs were greater (median 5·94 (range 2·35–7·72) versus 4·30 (2·12–6·47) at 32 h; P = 0·015); the percentage retained isotope was lower (median 53·8 (range 6·5–100) versus 89·9 (38·4–100) per cent at 32 h; P = 0·002); GC velocity indices were greater (median 1·70 (range 1·18–1·92) versus 1·45 (0·98–1·80); P = 0·013); and T½ was shorter (median 38·3 (17·0–65·0) versus 57·0 (32·1–160·0) h; P = 0·003). Percentage tracer retained at 32 h best discriminated major LARS from no LARS (area under curve (AUC) 0·828). Conclusion Patients with major LARS had accelerated colonic transit compared with those without LARS, which may help explain postoperative bowel dysfunction in this group. The percentage tracer retained at 32 h had the greatest AUC value in discriminating such patients.

show abstract

Effect of Glepaglutide, a Long‐Acting Glucagon‐Like Peptide‐2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial

Hvistendahl

Naimi

Enevoldsen

et al. 2020

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Background: Patients with short bowel syndrome (SBS) and distal-bowel resections lack neuroendocrine feedback regulations, potentially resulting in rapid gastrointestinal (GI) transit. The objective was to assess the efficacy of glepaglutide, a long-acting glucagon-like peptide-2 analog, on GI transit in patients with SBS. Methods: In this single-center, double-blind, dose-finding, phase 2 trial, patients with SBS were randomly assigned to 3 treatments (0.1, 1, and 10 mg) in a 2-period crossover design. Each treatment period included 3 weeks of daily, subcutaneous glepaglutide injections separated by a washout period of 4-8 weeks. Endpoints were changes from baseline and included scintigraphy, wireless motility capsule (WMC, SmartPill Given Imaging, Ltd, Yokneam, Israel), and paracetamol absorption test. Results: A total of 18 patients were randomized. In the 10-mg dose group (n = 9), glepaglutide significantly increased time to 10% gastric emptying (GE) of solids by 27 (4-50) minutes (adjusted mean [95% CI]), time to 50%GE of fluids by 40 (1-80) minutes, and time to 10% small bowel-emptying of solids by 21 (1-41) minutes. The WMC transit did not significantly change in any of the dose groups. The maximum paracetamol concentration significantly increased in the 10mg dose group; however, the area under the curve remained the same. Conclusion: The prolonged GI transit after glepaglutide treatment, along with demonstrated positive effects on intestinal mucosal growth and potential effects on GI hypersecretions, is believed to contribute to the observed beneficial effects on fecal output (primary endpoint) and associated improvement in intestinal absorption.

show abstract

Scintigraphic assessment of gastrointestinal motility: a brief review of techniques and data interpretation

Cited by 12 publications

References 79 publications

Motility Alterations in Celiac Disease and Non-Celiac Gluten Sensitivity

Motility Alterations in Celiac Disease and Non-Celiac Gluten Sensitivity

Colonic transit in patients after anterior resection: prospective, comparative study using single-photon emission CT/CT scintigraphy

Effect of Glepaglutide, a Long‐Acting Glucagon‐Like Peptide‐2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial

Contact Info

Product

Resources

About